Ephiphany raises $36M for anti-infection drugs
Epiphany, a San Francisco biotech company focused on developing anti-infective agents, said it has raised a $36 million first round of financing.
Wexford Capital, LLC led the financing, which included Windsor Bay Capital, Global Trust Ventures Management, CDIB BioScience Venture Management (CBVM) and several private… Continue Reading